Collectively, our results indicate that DT-061 inhibited tumor growth in a Bax/Bak-independent manner and suggest that PP2A activators could be used therapeutically for the treatment of multidrug-resistant CLL. This evidence concerns the gene BAX and B-cell chronic lymphocytic leukemia.